Pancreatic cancer patients continue to thrive after early trial of mRNA-based vaccine

Almost half of the contributors in an early trial of an mRNA-based vaccine to battle pancreatic cancer had been alive and nicely up to six years after therapy, in accordance to new analysis. NCS’s Brianna Keilar speaks with Dr. Vinod Balachandran, director of the Olayan Center for Cancer Vaccines at Memorial Sloan Kettering Cancer Center, who led the examine.